Collaborations

InvivoGen Therapeutics has established several ongoing research and development collaborations sponsored by the Cancer-Bio-Health Cluster of Toulouse.

I2MR - INSERM U858 (Toulouse - France)
InvivoGen Therapeutics and the French Institute for Health and Medical Research (Institut National de la Santé et de la Recherche Médicale / INSERM) U858 are collaborating since 2000 to develop a gene therapy strategy for the treatment of pancreatic cancer. This strategy is based on the dck::umk suicide gene coupled to the chemotherapeutic agent gemcitabine. A phase I/II clinical trial to evaluate this strategy (TherGAP) is expected to start in 2008.

UMR-CNRS-6101 (Limoges - France)
InvivoGen Therapeutics has initiated a collaboration with the joint research unit UMR-CNRS-6101 for the development of immunoglobulin A (IgA) as research reagents and therapeutic agents.


I2MR - INSERM U858
InvivoGen Therapeutics has signed a contract with the INSERM U858 to manufacture clinical lots of the pCpG plasmid for the TherGAP clinical trial (pancreatic cancer).


Transgene
InvivoGen Therapeutics has granted Transgene an exclusive license with covering the use of the fcy::fur suicide gene for gene therapy of 5-FU sensitive tumors.